These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 16572266)

  • 21. Alprazolam absorption kinetics affects abuse liability.
    Mumford GK; Evans SM; Fleishaker JC; Griffiths RR
    Clin Pharmacol Ther; 1995 Mar; 57(3):356-65. PubMed ID: 7697954
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sex-related elevation in cortisol during chronic treatment with alprazolam associated with enhanced cognitive performance.
    Pomara N; Willoughby LM; Ritchie JC; Sidtis JJ; Greenblatt DJ; Nemeroff CB
    Psychopharmacology (Berl); 2005 Nov; 182(3):414-9. PubMed ID: 16001108
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Differential effects of alprazolam on the baseline and fear-potentiated startle reflex in humans: a dose-response study.
    Riba J; Rodríguez-Fornells A; Urbano G; Morte A; Antonijoan R; Barbanoj MJ
    Psychopharmacology (Berl); 2001 Oct; 157(4):358-67. PubMed ID: 11605094
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Behavioral effects of alprazolam in humans.
    Kelly TH; Foltin RW; Serpick E; Fischman MW
    Behav Pharmacol; 1997 Feb; 8(1):47-57. PubMed ID: 9833000
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ramelteon: a novel hypnotic lacking abuse liability and sedative adverse effects.
    Johnson MW; Suess PE; Griffiths RR
    Arch Gen Psychiatry; 2006 Oct; 63(10):1149-57. PubMed ID: 17015817
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tandospirone and alprazolam: comparison of behavioral effects and abuse liability in humans.
    Evans SM; Troisi JR; Griffiths RR
    J Pharmacol Exp Ther; 1994 Nov; 271(2):683-94. PubMed ID: 7965783
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of cognitive function in healthy older subjects treated with fesoterodine.
    Kay GG; Maruff P; Scholfield D; Malhotra B; Whelan L; Darekar A; Martire DL
    Postgrad Med; 2012 May; 124(3):7-15. PubMed ID: 22691894
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of prolonged-release melatonin, zolpidem, and their combination on psychomotor functions, memory recall, and driving skills in healthy middle aged and elderly volunteers.
    Otmani S; Demazières A; Staner C; Jacob N; Nir T; Zisapel N; Staner L
    Hum Psychopharmacol; 2008 Dec; 23(8):693-705. PubMed ID: 18763235
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anxiolytics and memory: a comparison of lorazepam and alprazolam.
    Kumar R; Mac DS; Gabrielli WF; Goodwin DW
    J Clin Psychiatry; 1987 Apr; 48(4):158-60. PubMed ID: 3558328
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cognitive and psychomotor effects of risperidone in schizophrenia and schizoaffective disorder.
    Houthoofd SA; Morrens M; Sabbe BG
    Clin Ther; 2008 Sep; 30(9):1565-89. PubMed ID: 18840365
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cognitive testing in early-phase clinical trials: development of a rapid computerized test battery and application in a simulated Phase I study.
    Collie A; Darekar A; Weissgerber G; Toh MK; Snyder PJ; Maruff P; Huggins JP
    Contemp Clin Trials; 2007 Jul; 28(4):391-400. PubMed ID: 17267292
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Abecarnil and alprazolam in humans: behavioral, subjective and reinforcing effects.
    Mumford GK; Rush CR; Griffiths RR
    J Pharmacol Exp Ther; 1995 Feb; 272(2):570-80. PubMed ID: 7853170
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The acute effects of zolpidem, administered alone and with alcohol, on cognitive and psychomotor function.
    Wilkinson CJ
    J Clin Psychiatry; 1995 Jul; 56(7):309-18. PubMed ID: 7615484
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The use of effect sizes to characterize the nature of cognitive change in psychopharmacological studies: an example with scopolamine.
    Fredrickson A; Snyder PJ; Cromer J; Thomas E; Lewis M; Maruff P
    Hum Psychopharmacol; 2008 Jul; 23(5):425-36. PubMed ID: 18421801
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Influence of dosing regimen on alprazolam and metabolite serum concentrations and tolerance to sedative and psychomotor effects.
    Smith RB; Kroboth PD
    Psychopharmacology (Berl); 1987; 93(1):105-12. PubMed ID: 3114808
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of the use of hypnotics on cognition.
    Vermeeren A; Coenen AM
    Prog Brain Res; 2011; 190():89-103. PubMed ID: 21531246
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Abrupt discontinuation of alprazolam and cognitive style in patients with panic disorder: early effects on mood, performance, and vital signs.
    Uhlenhuth EH; Starcevic V; Qualls C; Antal EJ; Matuzas W; Javaid JI; Barnhill J
    J Clin Psychopharmacol; 2006 Oct; 26(5):519-23. PubMed ID: 16974197
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetic-pharmacodynamic modeling of stimulatory and sedative effects of alprazolam: timing performance deficits.
    Lau CE; Heatherington AC
    J Pharmacol Exp Ther; 1997 Dec; 283(3):1119-29. PubMed ID: 9399984
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A neurophysiological study of the detrimental effects of alprazolam on human action monitoring.
    Riba J; Rodríguez-Fornells A; Münte TF; Barbanoj MJ
    Brain Res Cogn Brain Res; 2005 Oct; 25(2):554-65. PubMed ID: 16168630
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The benzodiazepine alprazolam dissociates contextual fear from cued fear in humans as assessed by fear-potentiated startle.
    Grillon C; Baas JM; Pine DS; Lissek S; Lawley M; Ellis V; Levine J
    Biol Psychiatry; 2006 Oct; 60(7):760-6. PubMed ID: 16631127
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.